ScripMeiraGTx hopes to take a gene therapy candidate for Parkinson’s disease into Phase III based on positive efficacy and safety data from a small Phase II study that showed significant improvement on a d
ScripActuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest
In VivoNeurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene
In VivoDeal volume was down last year both in M&A and alliances, but valuations rose. Early in 2023, Pfizer Inc. set the tone for a year of moving on from the COVID-19 pandemic by agreeing to pay $43bn for